Approval · Notice of Compliance 18566 · 2016
FETZIMA: Notice of Compliance 18566
Issued October 13, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18566
- Date
- October 13, 2016
- Company
- Allergan Pharma Co.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
Products in this notice
Medicinal ingredients
- LEVOMILNACIPRAN 20 MG per CAP
- LEVOMILNACIPRAN 40 MG per CAP
- LEVOMILNACIPRAN 80 MG per CAP
- LEVOMILNACIPRAN 120 MG per CAP